Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression.
There is emerging evidence that aldosterone can promote diastolic dysfunction and cardiac fibrosis independent of blood pressure effects, perhaps through increased oxidative stress and inflammation. Accordingly, this investigation was designed to ascertain if mineralocorticoid receptor blockade improves diastolic dysfunction independently of changes in blood pressure through actions on myocardial oxidative stress and fibrosis. We used young transgenic (mRen2)27 [TG(mRen2)27] rats with increases in both tissue ANG II and circulating aldosterone, which manifests age-related increases in hypertension and cardiac dysfunction. Male TG(mRen2)27 and age-matched Sprague-Dawley rats were treated with either a low dose (∼1 mg·kg(-1)·day(-1)) or a vasodilatory, conventional dose (∼30 mg·kg(-1)·day(-1)) of spironolactone or placebo for 3 wk. TG(mRen2)27 rats displayed increases in systolic blood pressure and plasma aldosterone levels as well as impairments in left ventricular diastolic relaxation without changes in systolic function on cine MRI. TG(mRen2)27 hearts also displayed hypertrophy (left ventricular weight, cardiomyoctye hypertrophy, and septal wall thickness) as well as fibrosis (interstitial and perivascular). There were increases in oxidative stress in TG(mRen2)27 hearts, as evidenced by increases in NADPH oxidase activity and subunits as well as ROS formation. Low-dose spironolactone had no effect on systolic blood pressure but improved diastolic dysfunction comparable to a conventional dose. Both doses of spironolactone caused comparable reductions in ROS/3-nitrotryosine immunostaining and perivascular and interstitial fibrosis. These data support the notion mineralocorticoid receptor blockade improves diastolic dysfunction through improvements in oxidative stress and fibrosis independent of changes in systolic blood pressure.
Department of Internal Medicine, University of Missouri, Columbia, 65212, USA.
Javad
J
Habibi
Vincent G
VG
DeMarco
Lixin
L
Ma
Lakshmi
L
Pulakat
William E
WE
Rainey
Adam T
AT
Whaley-Connell
James R
JR
Sowers
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D006332:Cardiomegaly / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D004719:Endomyocardial Fibrosis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology; D019255:NADPH Oxidases / Q000096:biosynthesis; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D055647:Rats, Transgenic; D017382:Reactive Oxygen Species / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology; D013148:Spironolactone / Q000494:pharmacology; D014443:Tyrosine / Q000031:analogs & derivatives / Q000096:biosynthesis; D014665:Vasodilator Agents / Q000494:pharmacology; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology
D000451:Mineralocorticoid Receptor Antagonists; D017382:Reactive Oxygen Species; D014665:Vasodilator Agents; D013148:Spironolactone; C002744:3-nitrotyrosine; D014443:Tyrosine; D019255:NADPH Oxidases
Hypertension. 1994 Jun;23(6 Pt 2):1002-5
8206582
Cardiovasc Res. 1992 Jul;26(7):671-7
1423431
Hypertension. 2007 Feb;49(2):241-8
17190878
N Engl J Med. 2003 Apr 3;348(14):1309-21
12668699
Circulation. 2010 Jul 27;122(4):370-8
20625113
Circulation. 2007 Apr 3;115(13):1754-61
17372171
Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R946-54
17023667
N Engl J Med. 1999 Sep 2;341(10):709-17
10471456
Hypertension. 2002 Jul;40(1):23-7
12105133
Am J Physiol Heart Circ Physiol. 2002 Nov;283(5):H1802-10
12384457
Cardiol Rev. 2002 Mar-Apr;10(2):97-107
11895576
Hypertension. 2009 Feb;53(2):158-65
19114643
Biochem Biophys Res Commun. 2004 Jan 16;313(3):812-7
14697264
Ann Intern Med. 2009 Jun 2;150(11):776-83
19487712
Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E355-63
17440033
Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E103-9
18460596
Circ Res. 1990 Dec;67(6):1355-64
1700933
Endocrinology. 2002 Dec;143(12):4828-36
12446610
Circ Res. 1993 Sep;73(3):413-23
8348686
JAMA. 2003 Jan 8;289(2):194-202
12517230
Am Heart J. 1993 Jun;125(6):1710-6
8498315
Circulation. 2004 May 11;109(18):2213-20
15123520
Circulation. 1991 Jun;83(6):1849-65
1828192
Int J Obes Relat Metab Disord. 1998 Apr;22(4):363-8
9578243
Hypertension. 2010 Apr;55(4):880-8
20176997
Curr Opin Cardiol. 2000 Jul;15(4):264-72
11139090
Hypertension. 2002 Oct;40(4):477-84
12364350
Endocrinology. 2007 Aug;148(8):3773-80
17494996
Hypertension. 2005 Apr;45(4):773-9
15699470
Rev Esp Cardiol. 2010 Jul;63(7):779-87
20609311
J Am Coll Cardiol. 1984 Jun;3(6):1500-6
6232306
Hypertension. 1999 Apr;33(4):981-6
10205234
J Mol Cell Cardiol. 1994 Jul;26(7):809-20
7966349
Am J Pathol. 2002 Nov;161(5):1773-81
12414524
Am J Physiol Heart Circ Physiol. 2006 Jul;291(1):H336-43
16489102
Am J Physiol Heart Circ Physiol. 2011 Jan;300(1):H181-90
21057043
J Am Coll Cardiol. 2009 Oct 27;54(18):1674-82
19850207
Biochim Biophys Acta. 2004 Sep 17;1693(3):185-91
15363632
J Hypertens. 2008 Jul;26(7):1453-62
18551023
Hypertension. 2001 Feb;37(2 Pt 2):787-93
11230374
Hypertension. 2006 Apr;47(4):671-9
16505212
Hypertension. 2006 Apr;47(4):656-64
16505208
Circulation. 2005 Feb 1;111(4):420-7
15687129
N Engl J Med. 2006 Jul 20;355(3):251-9
16855265
J Mol Cell Cardiol. 2002 Dec;34(12):1655-65
12505063
FASEB J. 2006 Jul;20(9):1546-8
16720735